RESEARCH TRIANGLE PARK – Durham-based Bioventus, which develops orthobiologic products, is launching OSTEOAMP SELECT Fibers, an addition to its allograft line of bone graft substitutes for spine, foot and ankle, orthopaedic, and trauma surgeons.

An allograft is tissue transplanted from one person to another. The prefix “allo” derives from a Greek word meaning “other.”

Bioventus sources its material from U.S. tissue banks that collect and process donor bone.

Bioventus photo

OSTEOAMP SELECT Fibers.. Bioventus photo

OSTEOAMP SELECT Fibers are processed to retain essential growth factors supporting bone and the nanotextured fibers provide a conduit for cell migration. They also advance the handling properties of allograft bone graft substitutes. The interlocking fibers have high fluid retention and the ability to expand, while maintaining integrity and position.

These handling properties allow it to be easily molded and packed into place to conform to irregular bone voids. It can be used for the repair, replacement, or reconstruction of musculoskeletal defects.

The company explains that any significant trauma to bones can create a void as they break, but in spine surgery bone is shaved to prepare it for fusion. Allografts like OSTEOAMP SELECT Fibers are used to bridge the gap and foster healing of the bones.

There are roughly 700,000 spine surgeries occurring annually in the U.S.

The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing and are intended to help patients resume more-active lives.

Established in 2012, Bioventus is privately held, 51 percent owned by private equity and 49 percent by Smith and Nephew. The company has more than 700 employees worldwide, and 151 in its Durham headquarters. The company tells the North Carolina Biotechnology Center that it continues to hire for field sales and field-based market access roles to support its growth.

Its international headquarters is in Hoofddorp, The Netherlands. Bioventus also has offices in Memphis, Tennessee and Canada.  According to the company, in 2019, more than 400,000 people will use its products. The company works with patients, payers and health care providers in 30 countries throughout the world and generates $300 million in annual revenue.

(C) N.C. Biotech Center